Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by guildwood1on Mar 11, 2015 2:12pm
275 Views
Post# 23510399

Less than 250mg daily?

Less than 250mg daily?

If you evaluate this NR closely its not the most positive outlook in regards ot the direction of its lead drug.  Safe when less than 250mg daily? Thats a half of an extra strength Asprin a day.  Not exaclty an industry changer as most people utilizing NSAIDs are taking significantly more than that daily and their trials still indicated potential hepotoxicity in larger doses.  

That coupled with their clear requirement for more finanacing its not a sugar and smooth sailing for this company.  Still wish I was involved in this recent speculative run up but evaluating the company now to prior to the suspenion the fundamentals and potential is significantly less thus I wouldnt expect a quick rally back to old prices.  

Just my opinon but ill sideline this one for not. 

Bullboard Posts